Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together

Case Report: When cystic fibrosis, elexacaftor/tezacaftor/ivacaftor therapy, and alpha1 antitrypsin deficiency get together

In the last 10 years, the care of patients with cystic fibrosis (CF) has been revolutionized with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs, with a major impact on symptoms and life expectancy, especially considering the newest and highly effectiv...

Full description

Bibliographic Details
Main Authors: Rachel Kinuani, Jessica Ezri, Yann Kernen, Isabelle Rochat, Sylvain Blanchon
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Pediatrics
Subjects:
cystic fibrosis
CFTR modulator
ELX/TEZ/IVA
CF liver disease
drug-induced liver injury
Z allele
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2024.1378744/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2024.1378744/full

Similar Items